Fig. 6: Biomarker capacity of the four CpG sites and association between the cg47630224-MSH2 and breast cancer risk in independent validation cohorts. | npj Precision Oncology

Fig. 6: Biomarker capacity of the four CpG sites and association between the cg47630224-MSH2 and breast cancer risk in independent validation cohorts.

From: Methylation marks in blood DNA reveal breast cancer risk in patients fulfilling hereditary disease criteria

Fig. 6

a Breast cancer risk of the four hypermethylated CpG sites. b ROC performance of the four CpG sites. c Combinatorial analysis of sensitivity and specificity for 11 CpG site combinations. Yellow bubbles represent the best marker combinations (Se >70%, Sp >60%), referred to as “gold markers”. d Biomarker capacity of gold marker combinations 7, 10, and 11. e Differential methylation analysis of cg47630224-MSH2 in three international cohorts. f Association of cg47630224-MSH2 site with BC risk in three cohorts. g Biomarker capacity of cg47630224-MSH2 site in all cohorts: Australia (blue), Uruguay (green), Italy (red). BC breast cancer, OR Odds Ratio, 95% CI 95% confidence intervals, AUC area under curve, Sp specificity, Se sensitivity. Double asterisk (**) for p < 0.01, triple asterisk (***) for p < 0.001.

Back to article page